Various drugs that target the complex NF-kB pathway at different levels of the pathway are in development for the treatment of inflammatory conditions, such as rheumatoid arthritis, autoimmune diseases, and cancer, and some of these drugs have already gained FDA approval [7,85]. The gene discussed is NFKB1; the disease is rheumatoid arthritis.